Document ID: EPA-HQ-OPP-2005-0200-0022
Agency: epa
Document Type: Supporting & Related Material
Title: 
Posted Date: 2010-10-25T04:00Z

Meeting Summary

EPA/Arch Chemical/Dow Chemical/Steptoe & Johnson

October 6, 2010, 2:00 PM to 3:00 PM

Room S-7100, 2777 S. Crystal Drive, Arlington, VA 22202

Participants

Dow Chemical, Arch Chemical and Steptoe & Johnson Registrants: Joanne
Ryder, Nick Skoulis, George Hazleton, Gary Schifilliti, Elizabeth Brown,
Judy Hauswirth, Seth Goldberg

EPA: Stephen Dapson, A. Najm Shamim, Steven Malish, PV Shah, Yintak Woo,
Jonathan Chen, Nader Elkassabany, Tim McMahon, Mark Hartman, Lance
Wormell, Mary Manibusan, Rebecca von dem Hagen

Summary

On Wednesday, October 6, 2010, AD hosted a meeting with
1,2-Benzisoththiazolin-3-one (BIT) registrants Arch Chemical and Dow
Chemical.  The registrants requested this meeting to discuss the
Agency’s preliminary response to waiver requests for the chronic
toxicity and carcinogenicity studies required through the March 2008
post-RED DCI.  During the meeting, the registrants presented an overview
of BIT, information on isothiazolinone biocides and presented their
argument that the required BIT data should be bridged from existing data
on other isothiazolinone biocides (OIT, DCOIT, CMIT/MIT, and MIT).  The
registrants also questioned the need for additional studies noted in the
July 2010 memo.

Next Steps

The Agency requested more information on (1) the impact of radioactivity
in the repeated dose metabolic study on the thyroid and (2) the
radiolabeling of the Benzene ring in metabolism studies.  The receipt of
this additional information will enable the Agency to make a decision on
the waiver requests.

Page   PAGE  1  of   NUMPAGES   1